EMERALD-Y90: Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy

Is This Study For You?

Let's Get Started!

Details
Age
Adult
Locations

University of Colorado Hospital

Principal Investigator
Photograph of Jonathan Lindquist

Jonathan Lindquist

Study ID

Protocol Number: 23-1827

More information available at ClinicalTrials.gov: NCT06040099

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers